Esperion Therapeutics, Inc.
Símbolo: ESPR
NASDAQ
2.05
USDPrecio de mercado actual
-0.9875
Ratio PER
0.0209
Ratio PEG
349.36M
Capitalización MRK
- 0.00%
Rendimiento DIV
Esperion Therapeutics, Inc. (ESPR) Estados Financieros
Balance de situación
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2002 | 2001 | 2000 | 1999 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 497.89 | 82.2 | 124.8 | 208.9 | |||||||||||||||||
balance-sheet.row.short-term-investments | 17.43 | 0 | 42.1 | 50.4 | |||||||||||||||||
balance-sheet.row.net-receivables | 168.33 | 48.5 | 33.7 | 22.9 | |||||||||||||||||
balance-sheet.row.inventory | 202.09 | 65.6 | 35.2 | 34.4 | |||||||||||||||||
balance-sheet.row.other-current-assets | 20.89 | 4.7 | 9.9 | 62.8 | |||||||||||||||||
balance-sheet.row.total-current-assets | 902.02 | 201.1 | 246.7 | 329 | |||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 11.3 | 4.7 | 1.2 | 2.6 | |||||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.intangible-assets | 0.22 | 0.1 | 0.1 | 0.1 | |||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0.22 | 0.1 | 0.1 | 0.1 | |||||||||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 42.1 | 50.4 | |||||||||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | -50.4 | |||||||||||||||||
balance-sheet.row.other-non-current-assets | -3.72 | 0 | -42.1 | 50 | |||||||||||||||||
balance-sheet.row.total-non-current-assets | 11.52 | 4.7 | 1.3 | 52.6 | |||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.total-assets | 913.55 | 205.8 | 247.9 | 381.6 | |||||||||||||||||
balance-sheet.row.account-payables | 99.56 | 31.7 | 23 | 17.6 | |||||||||||||||||
balance-sheet.row.short-term-debt | 38.29 | 36.4 | 0.4 | 1.4 | |||||||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.long-term-debt-total | 1288.3 | 501.5 | 260.6 | 258.8 | |||||||||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0.6 | |||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||||||||
balance-sheet.row.other-current-liab | 285.83 | 62.7 | 65.4 | 48.7 | |||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 1983.59 | 504.6 | 479.4 | 505.2 | |||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.capital-lease-obligations | 9.46 | 3 | 1 | 1.9 | |||||||||||||||||
balance-sheet.row.total-liab | 2480.18 | 660.8 | 571.7 | 578.5 | |||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.common-stock | 0.42 | 0.1 | 0.1 | 0.1 | |||||||||||||||||
balance-sheet.row.retained-earnings | -5895.67 | -1549.3 | -1340 | -1106.4 | |||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 3256.52 | 1094.2 | -0.1 | 0 | |||||||||||||||||
balance-sheet.row.total-stockholders-equity | -2638.73 | -455 | -1340 | -1106.4 | |||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | -158.55 | 205.8 | -768.3 | -527.8 | |||||||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.total-equity | -2638.73 | -455 | -1340 | -1106.4 | |||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | -158.55 | - | - | - | |||||||||||||||||
Total Investments | 17.43 | 0 | 84.2 | 100.9 | |||||||||||||||||
balance-sheet.row.total-debt | 1329.61 | 540.9 | 260.9 | 260.2 | |||||||||||||||||
balance-sheet.row.net-debt | 849.15 | 458.7 | 136.2 | 51.3 |
Estado de tesorería
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2002 | 2001 | 2000 | 1999 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -209.25 | -209.2 | -233.7 | -269.1 | |||||||||||||||||
cash-flows.row.depreciation-and-amortization | 0.16 | 0.2 | 0.5 | 0.6 | |||||||||||||||||
cash-flows.row.deferred-income-tax | -17.56 | 36.5 | 0 | -2.6 | |||||||||||||||||
cash-flows.row.stock-based-compensation | 11.96 | 12 | 15.2 | 24.3 | |||||||||||||||||
cash-flows.row.change-in-working-capital | 13.68 | 13.7 | -3.4 | -52.5 | |||||||||||||||||
cash-flows.row.account-receivables | -14.77 | -14.8 | -10.8 | -10.5 | |||||||||||||||||
cash-flows.row.inventory | -30.42 | -30.4 | -0.8 | -18.3 | |||||||||||||||||
cash-flows.row.account-payables | 8.68 | 8.7 | 5.6 | -34.1 | |||||||||||||||||
cash-flows.row.other-working-capital | 50.18 | 50.2 | 2.6 | 10.4 | |||||||||||||||||
cash-flows.row.other-non-cash-items | 65.52 | 11.5 | 46.5 | 35.5 | |||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -135.49 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | -59.9 | -50.5 | |||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 42.5 | 42.5 | 68 | 0 | |||||||||||||||||
cash-flows.row.other-investing-activites | 42.5 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 42.5 | 42.5 | 8.1 | -50.5 | |||||||||||||||||
cash-flows.row.debt-repayment | -15.51 | -15.5 | -58.2 | -0.8 | |||||||||||||||||
cash-flows.row.common-stock-issued | 13.52 | 66 | 90.8 | 218.7 | |||||||||||||||||
cash-flows.row.common-stock-repurchased | -0.02 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.other-financing-activites | 53.81 | 0 | -50.2 | 50.3 | |||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 50.46 | 50.5 | 32.6 | 268.2 | |||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.net-change-in-cash | -42.53 | -42.5 | -134.1 | -46.1 | |||||||||||||||||
cash-flows.row.cash-at-end-of-period | 480.46 | 82.2 | 124.8 | 258.9 | |||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 522.99 | 124.8 | 258.9 | 305 | |||||||||||||||||
cash-flows.row.operating-cash-flow | -135.49 | -135.5 | -174.8 | -263.8 | |||||||||||||||||
cash-flows.row.capital-expenditure | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.free-cash-flow | -135.49 | -135.5 | -174.8 | -263.8 |
Fila de la Cuenta de Resultados
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2002 | 2001 | 2000 | 1999 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 116.33 | 116.3 | 75.5 | 78.4 | |||||||||||||||||
income-statement-row.row.cost-of-revenue | 43.27 | 43.4 | 27 | 14.2 | |||||||||||||||||
income-statement-row.row.gross-profit | 73.06 | 72.9 | 48.5 | 64.2 | |||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||||
income-statement-row.row.research-development | 86.11 | - | - | - | |||||||||||||||||
income-statement-row.row.selling-general-administrative | 29.82 | - | - | - | |||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 15.6 | - | - | - | |||||||||||||||||
income-statement-row.row.other-expenses | 22.52 | 5.3 | 2.7 | 4 | |||||||||||||||||
income-statement-row.row.operating-expenses | 248.79 | 228.5 | 228 | 291 | |||||||||||||||||
income-statement-row.row.cost-and-expenses | 271.9 | 271.9 | 255 | 305.2 | |||||||||||||||||
income-statement-row.row.interest-income | 5.11 | 4.8 | 2.6 | 0.1 | |||||||||||||||||
income-statement-row.row.interest-expense | -0.09 | 59 | 56.8 | 46.4 | |||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 15.6 | - | - | - | |||||||||||||||||
income-statement-row.row.total-other-income-expensenet | -53.69 | -53.7 | -54.2 | -42.4 | |||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.other-operating-expenses | 22.52 | 5.3 | 2.7 | 4 | |||||||||||||||||
income-statement-row.row.total-operating-expenses | -53.69 | -53.7 | -54.2 | -42.4 | |||||||||||||||||
income-statement-row.row.interest-expense | -0.09 | 59 | 56.8 | 46.4 | |||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 1.36 | 0.2 | 2.7 | 4 | |||||||||||||||||
income-statement-row.row.ebitda-caps | -154.28 | - | - | - | |||||||||||||||||
income-statement-row.row.operating-income | -155.56 | -155.6 | -179.5 | -226.7 | |||||||||||||||||
income-statement-row.row.income-before-tax | -209.25 | -209.2 | -233.7 | -269.1 | |||||||||||||||||
income-statement-row.row.income-tax-expense | 27.42 | 0 | 54.2 | 49.7 | |||||||||||||||||
income-statement-row.row.net-income | -236.75 | -209.2 | -287.8 | -318.8 |
Preguntas frecuentes
Cuánto es Esperion Therapeutics, Inc. (ESPR) activos totales?
Esperion Therapeutics, Inc. (ESPR) los activos totales son 205796000.000.
¿Cuáles son los ingresos anuales de la empresa?
Los ingresos anuales son 66219000.000.
¿Cuál es el margen de beneficios de la empresa?
El margen de beneficios de la empresa es 0.628.
¿Qué es el flujo de caja libre de la empresa?
El flujo de caja libre es -1.205.
¿Cuál es el margen de beneficio neto de la empresa?
El margen de beneficio neto es -2.035.
¿Cuáles son los ingresos totales de la empresa?
Los ingresos totales son -1.337.
¿Qué es Esperion Therapeutics, Inc. (ESPR) beneficio neto (ingresos netos)?
El beneficio neto (ingresos netos) es -209248000.000.
¿Cuál es la deuda total de la empresa?
La deuda total es 540947000.000.
¿Cuál es la cifra de gastos de explotación?
Los gastos de explotación son 228466000.000.
¿Cuál es la cifra de tesorería de la empresa?
La tesorería de la empresa es 82248000.000.